ArticleBMC cancer2013
CD26 expression on T-anaplastic large cell lymphoma (ALCL) line Karpas 299 is associated with increased expression of versican and MT1-MMP and enhanced adhesion.
Article in BMC cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- From Cell Lines to Avatars: Charting the Future of Preclinical Modeling in T-Cell Malignancies.Cells · 2026Review
- 4(3International journal of molecular sciences · 2025Review
- DPP4, a potential tumor biomarker, and tumor therapeutic target: review.Molecular biology reports · 2025Review
- Using adjusted local assortativity with Molecular Pixelation unveils colocalization of membrane proteins with immunological significance.Frontiers in immunology · 2024Article
- Cholesterol depletion decreases adhesion of non-small cell lung cancer cells to E-selectin.American journal of physiology. Cell physiology · 2023Article
- Potential clinical implications of CD4Journal of translational medicine · 2023Article
- Review
- Defining the versican interactome in lung health and disease.American journal of physiology. Cell physiology · 2022Review
- Leukocyte Membrane Enzymes Play the Cell Adhesion Game.Frontiers in immunology · 2021Review
- CD26-Related Serum Biomarkers: sCD26 Protein, DPP4 Activity, and Anti-CD26 Isotype Levels in a Colorectal Cancer-Screening Context.Disease markers · 2020Article
- Surface expression marker profile in colon cancer cell lines and sphere-derived cells suggests complexity in CD26Biology open · 2019Article
- A multi-center retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers.Molecular and clinical oncology · 2019Article
- CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma.Blood cancer journal · 2018Article
- Molecular Evidence of Adenosine Deaminase Linking Adenosine AFrontiers in pharmacology · 2018Article
- Probing chromatin landscape reveals roles of endocardial TBX20 in septation.The Journal of clinical investigation · 2016Article
- DPPIV/CD26: a tumor suppressor or a marker of malignancy?Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.Biochimica et biophysica acta · 2015Review
- CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis.PloS one · 2015Article
- A role for versican in the development of leiomyosarcoma.The Journal of biological chemistry · 2014Article
- Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.The FEBS journal · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCD26/dipeptidyl peptidase IV (DPPIV) is a multifunctional membrane protein with a key role in T-cell biology and also serves as a marker of aggressive cancers, including T-cell malignancies.
methodsVersican expression was measured by real-time RT-PCR and Western blots. Gene silencing of versican in parental Karpas 299 cells was performed using transduction-ready viral particles. The effect of versican depletion on surface expression of MT1-MMP was monitored by flow cytometry and surface biotinylation. CD44 secretion/cleavage and ERK (1/2) activation was followed by Western blotting. Collagenase I activity was measured by a live cell assay and in vesicles using a liquid-phase assay. Adhesion to collagen I was quantified by an MTS assay.
resultsVersican expression was down-regulated in CD26-depleted Karpas 299 cells compared to the parental T-ALCL Karpas 299 cells. Knock down of versican in the parental Karpas 299 cells led to decreased MT1-MMP surface expression as well as decreased CD44 expression and secretion of the cleaved form of CD44. Parental Karpas 299 cells also exhibited higher collagenase I activity and greater adhesion to collagenase I than CD26-knockdown or versican-knockdown cells. ERK activation was also highest in parental Karpas 299 cells compared to CD26-knockdown or versican-knockdown clones.
conclusionsOur data indicate that CD26 has a key role in cell adhesion and invasion, and potentially in tumorigenesis of T-cell lines, through its association with molecules and signal transduction pathways integral to these processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.